Rancho BioSciences

We're #hiring a new Scientist / Sr. Scientist Data Clinical Curator - REMOTE in United States. Apply today or share this post with your network.

Epigenetics & Chromatin! Check out our latest publication, “CREdb: A Comprehensive Database of Cis Regulatory Elements and their Activity in Human Cells and Tissues.” This groundbreaking work is a collaborative effort between the incredible teams at Takeda and Rancho BioSciences. Key Highlights: - CREdb is a meticulously curated database designed to provide extensive data on cis regulatory elements. - It offers invaluable insights into their activity across various human cells and tissues. - This resource aims to accelerate research in genetics, molecular biology, and related fields. We believe CREdb will be a crucial asset for researchers, offering a robust foundation for further advancements in understanding gene regulation and its implications in health and disease. Huge congratulations and thanks to all the brilliant minds involved in this project. Your dedication and hard work have made this invaluable tool possible. For those interested in exploring CREdb and diving into the depths of epigenetic landscapes, check out the publication https://hubs.ly/Q02LZjN60 . #Epigenetics #Chromatin #Genomics #Bioinformatics #Takeda #RanchoBioSciences #REdb #GeneRegulation #BiomedicalResearch

Important Research Update in Neuroscience! A pivotal publication in *JCI Insight* that delves into the complexities of Huntington’s disease. Our latest study, "Benefits of Global Mutant Huntingtin Lowering Diminish Over Time in a Huntington’s Disease Mouse Model," sheds light on the time-sensitive impacts of therapeutic strategies in advancing neurological research. This groundbreaking research highlights that while initial lowering of mutant huntingtin proves beneficial, these effects diminish over time in Huntington’s disease mouse models. These findings underscore the intricate challenges of long-term treatment strategies in neurodegenerative diseases and reinforce the need for sustained and adaptive therapeutic approaches. At Rancho BioSciences, our subject matter expertise in neuroscience and data analysis played a crucial role in driving this research forward. We are incredibly proud of the meticulous work of our talented team and the insights they've brought to this vital field of study. A huge thank you to our dedicated researchers and collaborators who have contributed to this significant advancement. Your unwavering commitment to neuroscience is truly inspiring. Read the full study here for a detailed understanding of our findings: https://lnkd.in/gBKvzM5w Together, we continue to push the boundaries of what's possible in neuroscience, striving for better treatment solutions

🌟 Proud Collaboration Announcement! 🌟    We are thrilled to share a significant milestone achieved in collaboration with NCATS: the launch of NCATS Inxight Drugs, a comprehensive and curated portal designed to accelerate translational research!    🔬 NCATS Inxight Drugs provides researchers with an expansive, meticulously curated database of drug information, facilitating better understanding and innovative solutions in drug discovery and development. This user-friendly portal integrates detailed drug data, enabling seamless access to critical information that drives translational research forward.    At Rancho BioSciences, we are honored to have contributed our expertise in data curation and management to this groundbreaking project. It's collaborations like these that reinforce our commitment to transforming data into meaningful, actionable insights for the scientific community.    👏 A heartfelt thank you to the dedicated teams at NCATS and Rancho BioSciences for their hard work and relentless pursuit of scientific excellence. Together, we're making complex drug research more accessible and impactful for everyone in the field.    Explore NCATS Inxight Drugs and see how it's set to revolutionize translational research: NCATS Inxight Drugs: a comprehensive and curated portal for translational research | Nucleic Acids Research | Oxford Academic https://lnkd.in/eCjNQUzs Onward to more innovative breakthroughs! 🚀🔍✨    Sharing Knowledge and Insights - Rancho Publications https://lnkd.in/etN7V9Gv #TranslationalResearch #NCATSInxightDrugs #RanchoBioSciences #DrugDiscovery

🌟 Exciting News in Bioinformatics! 🌟  In collaboration with the NIH, Rancho has made significant contributions to the field of bioinformatics. Our latest research, published in *Biofabrication* journal, is focused on the innovative "Stress-free Cell Aggregation by Using the CEPT Cocktail Enhances Embryoid Body and Organoid Fitness."    🔬 This groundbreaking study introduces a stress-free cell aggregation technique via the CEPT cocktail, significantly improving the fitness and viability of embryoid bodies and organoids. This advancement holds enormous potential for regenerative medicine and tissue engineering, paving the way for more reliable and efficient organoid and stem cell research.    👏 A huge thank you to our talented team of scientists and collaborators at the NIH for their dedication and hard work. Your contributions are invaluable in driving forward the boundaries of scientific discovery and innovation.    For a detailed read on this transformative study, check out the full publication here: https://lnkd.in/ezRymmTz   Together, we're not just imagining the future of medicine; we're building it. 🚀🔬 #Biofabrication #RanchoBioSciences #NIH #CEPTCocktail #StemCellResearch #RegenerativeMedicine #InnovateToHeal #Bioinformatics

🔬📝 Science Publication alert! 🎉  Featured in *Cancer Cell*, Nabet et al. delve deep into the complexities of immune heterogeneity within small-cell lung cancer (SCLC). This study offers invaluable insights into how varying immune environments within tumors can influence the efficacy of immune checkpoint blockade therapies. This important study advances our knowledge around personalized and effective treatment strategies for SCLC patients. Our subject matter experts live for this kind of work. Partnering with researchers to turn their data into insights!    👏 Kudos to our dedicated researchers and collaborators who made this breakthrough possible. Your innovation and relentless pursuit of knowledge continue to push the boundaries of cancer research.    Full article here: https://lnkd.in/es9Nt375 Together, we are paving the way for a future where every patient receives the most precise and effective treatment available. Onward and upward! 💪✨    #CancerResearch #RanchoBioSciences #ImmuneCheckpointBlockade #SCLC #PrecisionMedicine #InnovateToCure 

Pushing the boundaries of what's possible in genetic research and therapy development. Recently published in *Brain* (2024), titled "A CAG Repeat Threshold for Therapeutics Targeting Somatic Instability in Huntington’s Disease." 🔬📜 New insights into the genetic thresholds could guide the development of targeted therapies for Huntington's disease. This paper not only enhances our understanding of the disease mechanism but also opens new avenues for therapeutic intervention that could potentially alter the course of this devastating illness. As we continue our research and collaborations, I am optimistic about the future of Huntington’s disease treatment. Stay tuned for more updates as we advance our mission to translate scientific discoveries into clinical solutions.  Let’s keep driving science forward for a better tomorrow!  https://lnkd.in/e_E6_d-2 #HuntingtonsDisease #Genetics #Biotech #RanchoBioSciences #ScientificResearch #Innovation 

🔬💡Working with Data structures and CMC? Join us as we discuss our POC project on tablet compression, building upon the established NIIMBL and ISA-88 standards. We’ve designed flexible data-models and curated extensive datasets with specific manufacturing processes in mind. This approach streamlines the laborious tasks of testing provenance, data tracking, and worldwide terminology harmonization, reducing time to market and increasing production yields. With this much useable data in combination with Generative AI, we are just scratching the surface! Join Matthew Metzger from Merck and Rancho BioSciences own Daniel (Danny) Cooper as they discuss their findings and answer your questions. Register even if you can't join live and we'll send you the recording. https://lnkd.in/eY_2whGq When: June 18th, 11am EST #Merck, #CMC, #GenAI, #AI, #Ontology, #BigData, #LifeSciences, #Pharma, #DrugDiscovery

We are thrilled to share that Rancho BioSciences presented a poster at the PRISME Forum this May. Our presentation, titled "Quality Data and Creative Approaches Drive GenAI’s Transformative Journey in Biopharma," highlighted the cutting-edge ways we are leveraging high-quality data and innovative methodologies to propel Generative AI's impact in the biopharma industry. The forum provided an excellent opportunity to connect with industry leaders, share insights, and discuss the future of biopharma driven by GenAI. We are incredibly proud of our team's dedication and the enthusiastic reception our work received. A heartfelt thank you to everyone who attended and contributed to the enriching discussions. Your support and interest are invaluable! https://lnkd.in/e9YqRHy4 #PRISMEForum2024 #RanchoBioSciences #GenAI #Biopharma #Innovation #DataQuality #CreativeApproaches

🔬💡We were so overwhelmed at the response to our POC presentation at BioIT on Data structures and CMC ontologies that we want to shout it from the rooftops! Our work is centered around tablet compression building upon the established NIIMBL and ISA-88 standards. We’ve designed flexible data-models and curated extensive datasets with specific manufacturing processes in mind. This approach streamlines the laborious tasks of testing provenance, data tracking, and worldwide terminology harmonization, reducing time to market and increasing production yields. With this much useable data in combination with Generative AI, we are just scratching the surface! 🚀 Join Matthew Metzger from Merck and Rancho BioSciences own Daniel (Danny) Cooper as they discuss their findings and answer your questions. Register even if you can't join live and we'll send you the recording. https://lnkd.in/eY_2whGq When: June 18th, 11am EST #Merck #CMC #GenAI #AI #Ontology #BigData #LifeSciences #Pharma #DrugDiscovery